Table 4.
Multivariate analysis of factors related to toxicity drug modifications.
| Months of follow up | ||
|---|---|---|
| 0 to 3 | 3 to 36 | |
| p-value HR (95% CI) | ||
| Gender | 0.002 | 0.870 |
| Female vs. Male | 2.42 (1.39–4.24) | 1.05 (0.59–1.88) |
| Age, per 10-year increase | <0.001 | 0.188 |
| Age | 1.42 (1.16–1.74) | 1.13 (0.94–1.36) |
| Nucleoside backbone | 0.69 | |
| ABC3TC vs. D4T3TC | 0.56 (0.16–1.97) | 0.23 (0.08–0.68)* |
| ZDV3TC vs. D4T3TC | 1.06 (0.58–1.95) | 0.38 (0.20–0.72)* |
| Other/none vs. D4T3TC | 0.66 (0.21–2.11) | 1.24 (0.49–3.10)* |
| Type of CART | 0.061 | |
| 2NRT + 1PI vs. 2NRT + 1NNRT | 0.60 (0.33–1.12) | 1.49 (0.99–2.26)** |
| Other vs. 2NRT+ 1NNRT | 2.89 (0.77–10.81) | 3.41 (0.95–12.28)** |
Adjusted for time sequence and in the 3 to 36 months follow-up model also for the CD4 cell count (not significant) and distance from HIV center (not significant). HR – hazard ratio; CI – confidence interval; ABC – abacavir; 3TC – lamivudine; D4T – stavudine; ZDV – zidovudine; NRT – nucleoside reverse-transcriptase inhibitor; NNRT – nonnucleoside reverse-transcriptase inhibitor; PI – protease inhibitor.
*
At month 6; p=0.008 for the comparison ABC3TC vs. D4T3TC, p=0.003 for the comparison ZDV3TC vs. D4T3TC, p=0.648 for the comparison other/none vs. D4T3TC.
**
at month 15; p=0.06 for the comparison 2NRT+1PI vs. 2NRT+ 1NNRT, p=0.06 for the comparison other vs. 2NRT+1NNRT.